Last Price
43.36
Today's Change
+2.009 (4.86%)
Day's Change
42.04 - 43.57
Trading Volume
267,387
Market Cap
2 Billion
Shares Outstanding
49 Million
Avg Volume
346,717
Avg Price (50 Days)
46.75
Avg Price (200 Days)
45.64
PE Ratio
4336.00
EPS
0.01
Earnings Announcement
06-Nov-2024
Previous Close
41.35
Open
42.04
Day's Range
42.04 - 43.575
Year Range
30.18 - 54.1
Trading Volume
267,387
1 Day Change
4.86%
5 Day Change
1.10%
1 Month Change
-7.94%
3 Month Change
-7.11%
6 Month Change
-15.10%
Ytd Change
24.31%
1 Year Change
27.38%
3 Year Change
-14.70%
5 Year Change
213.07%
10 Year Change
1471.01%
Max Change
-96.13%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.